Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001721288 | SCV000528062 | benign | not provided | 2019-11-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000553740 | SCV000640594 | benign | Nemaline myopathy 2 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003226294 | SCV003922822 | likely benign | not specified | 2023-03-19 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001721288 | SCV005245954 | benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV000553740 | SCV002076990 | benign | Nemaline myopathy 2 | 2019-12-05 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004551469 | SCV004742824 | benign | NEB-related disorder | 2019-03-29 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |